IS ONLY REQUESTING AN ANTI-HCV TEST SUFFICIENT FOR HEPATITIS C SCREENING?

Rabia Deniz; Seda Karslı; Ömer Burak Ekinci; İlkana Kalantarova; Alp Atasoy; Mustafa Önel; Ali Ağaçfidan; Filiz Akyüz; Kadir Demir; Fatih Beşışık; Sabahattin Kaymakoğlu

Makale detayları

IS ONLY REQUESTING AN ANTI-HCV TEST SUFFICIENT FOR HEPATITIS C SCREENING?

Yazarlar:

Rabia Deniz | Seda Karslı | Ömer Burak Ekinci | İlkana Kalantarova | Alp Atasoy | Mustafa Önel | Ali Ağaçfidan | Filiz Akyüz | Kadir Demir | Fatih Beşışık | Sabahattin Kaymakoğlu

Yayıncı:

Istanbul University

Ana Başlıklar:

Sağlık Hizmetleri ve Sistemleri (Diğer)

Dergi:

İstanbul Tıp Fakültesi Dergisi Vol.87 Issue 3, pp.215-219

Belge Tipi:

Makale

Yayın Tarihi:

7/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001330649

pISSN:

1305-6441

Anahtar kelimeler:

Özet:

 Objective: Unless treated, a hepatitis C virus HCV infection is associated with high morbidity and mortality. The study investigates anti-HCV screening efficacy and treatment access rates for patients. Material and Method: This cross-sectional study screened all anti-HCV tests requested between January 2014-June 2017 from hospital records. Patient interviews were conducted by telephone-based interview. Result: The overall number of anti-HCV tests requested was 77,783, 1,373 of which were positive. Among these, the study interviewed 488 patients 266 females, 222 males; mean age52.8116.5 years and analyzed their tests. Further investigation with HCV-RNA had not been done in 69 14.1 anti-HCV positive patients. HCV-RNA was positive in 309 patients, 268 of whom were treated 86, while 41 were not 14. The main reasons for remaining untreated are: unknown 21, no patient follow up 28, or physician didnt indicate 19. Conclusion: In order to successfully eliminate HCV, the anti-HCV test alone is not enough. Informing patients about the results of the anti-HCV test and, if positive, referring them for the HCV-RNA test are important. When considering the high amount of untreated patients, linkage to care should be encouraged in HCV-RNA positive patients unless an absolute contraindication is present.

 Objective: Unless treated, a hepatitis C virus HCV infection is associated with high morbidity and mortality. The study investigates anti-HCV screening efficacy and treatment access rates for patients. Material and Method: This cross-sectional study screened all anti-HCV tests requested between January 2014-June 2017 from hospital records. Patient interviews were conducted by telephone-based interview. Result: The overall number of anti-HCV tests requested was 77,783, 1,373 of which were positive. Among these, the study interviewed 488 patients 266 females, 222 males; mean age52.8116.5 years and analyzed their tests. Further investigation with HCV-RNA had not been done in 69 14.1 anti-HCV positive patients. HCV-RNA was positive in 309 patients, 268 of whom were treated 86, while 41 were not 14. The main reasons for remaining untreated are: unknown 21, no patient follow up 28, or physician didnt indicate 19. Conclusion: In order to successfully eliminate HCV, the anti-HCV test alone is not enough. Informing patients about the results of the anti-HCV test and, if positive, referring them for the HCV-RNA test are important. When considering the high amount of untreated patients, linkage to care should be encouraged in HCV-RNA positive patients unless an absolute contraindication is present.

 Objective: Unless treated, a hepatitis C virus HCV infection is associated with high morbidity and mortality. The study investigates anti-HCV screening efficacy and treatment access rates for patients. Material and Method: This cross-sectional study screened all anti-HCV tests requested between January 2014-June 2017 from hospital records. Patient interviews were conducted by telephone-based interview. Result: The overall number of anti-HCV tests requested was 77,783, 1,373 of which were positive. Among these, the study interviewed 488 patients 266 females, 222 males; mean age52.8116.5 years and analyzed their tests. Further investigation with HCV-RNA had not been done in 69 14.1 anti-HCV positive patients. HCV-RNA was positive in 309 patients, 268 of whom were treated 86, while 41 were not 14. The main reasons for remaining untreated are: unknown 21, no patient follow up 28, or physician didnt indicate 19. Conclusion: In order to successfully eliminate HCV, the anti-HCV test alone is not enough. Informing patients about the results of the anti-HCV test and, if positive, referring them for the HCV-RNA test are important. When considering the high amount of untreated patients, linkage to care should be encouraged in HCV-RNA positive patients unless an absolute contraindication is present.

 Amaç: HCV enfeksiyonu, tedavi edilmediği sürece yüksek morbidite ve mortalite ile ilişkilidir. Bu çalışmada anti-HCV tarama etkinliği ve tedaviye erişim oranları araştırılmıştır. Gereç ve Yöntem: Bu kesitsel çalışmada Ocak 2014 ile Haziran 2017 tarihleri arasında istenen tüm anti-HCV testleri hastane kayıtlarından tarandı. Hasta görüşmeleri yüz yüze veya telefon ortamında yapıldı. Bulgular: İstenilen toplam anti-HCV testi sayısı 77783 olup, bunların 1373ü pozitif çıkmıştır. Bunlardan 266sı kadın, 222si erkek; yaş ortalaması 52,8116,5 yıl olan 488 hastayla görüşme yapılmıştır. Anti-HCV pozitif hastaların 69una 14,1 HCV-RNA ile ileri araştırma yapılmadığı saptandı. 309 hastada HCV-RNA pozitifti ve 268i tedavi almışken 86, 41i 14 tedavi edilmemişti. Tedavisiz kalmanın temel nedenleri ise bilinmeyen 21, takip edilmeyen hasta 28 ve hekimin endikasyon göstermemesi 19 olarak belirlendi. Sonuç: HCVnin başarılı bir şekilde eradike edilmesi için anti-anti-HCV testi tek başına yeterli değildir. Hastaların anti-HCV testi sonuçları hakkında bilgilendirilmesi; pozitif ise HCV-RNA testine başvurulması önemlidir. Tedavi edilmeyen hasta sayısının yüksek olduğu göz önüne alındığında, mutlak bir kontrendikasyon olmadığı sürece HCV-RNA pozitif hastalarda tedaviye yönlendirilme teşvik edilmelidir.

Makale detayları

IS ONLY REQUESTING AN ANTI-HCV TEST SUFFICIENT FOR HEPATITIS C SCREENING?

Yazarlar:

Rabia Deniz | Seda Karslı | Ömer Burak Ekinci | İlkana Kalantarova | Alp Atasoy | Mustafa Önel | Ali Ağaçfidan | Filiz Akyüz | Kadir Demir | Fatih Beşışık | Sabahattin Kaymakoğlu

Yayıncı:

Istanbul University

Ana Başlıklar:

Sağlık Hizmetleri ve Sistemleri (Diğer)

Dergi:

İstanbul Tıp Fakültesi Dergisi Vol.87 Issue 3, pp.215-219

Belge Tipi:

Makale

Yayın Tarihi:

7/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001330649

pISSN:

1305-6441

Hepatitis C virus infection

anti-HCV antibody

HCVRNA

screeningHepatit C enfeksiyonu

anti-HCV antikoru

HCV RNA

tarama

Sayı

Makale detayları

Yazarlar: Rabia Deniz | Seda Karslı | Ömer Burak Ekinci | İlkana Kalantarova | Alp Atasoy | Mustafa Önel | Ali Ağaçfidan | Filiz Akyüz | Kadir Demir | Fatih Beşışık | Sabahattin Kaymakoğlu

Yayıncı: Istanbul University

Ana Başlıklar: Sağlık Hizmetleri ve Sistemleri (Diğer)

Dergi: İstanbul Tıp Fakültesi Dergisi Vol.87 Issue 3, pp.215-219

Belge Tipi: Makale

Yayın Tarihi: 7/2024

Belge Dili: İngilizce

Document ID (Org No.): 2001330649

pISSN: 1305-6441

Sayı

Yazarlar:

Rabia Deniz | Seda Karslı | Ömer Burak Ekinci | İlkana Kalantarova | Alp Atasoy | Mustafa Önel | Ali Ağaçfidan | Filiz Akyüz | Kadir Demir | Fatih Beşışık | Sabahattin Kaymakoğlu

Yayıncı:

Istanbul University

Ana Başlıklar:

Sağlık Hizmetleri ve Sistemleri (Diğer)

Dergi:

İstanbul Tıp Fakültesi Dergisi Vol.87 Issue 3, pp.215-219

Belge Tipi:

Makale

Yayın Tarihi:

7/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001330649

pISSN:

1305-6441